University of Colorado, Anschutz Medical Campus
Welcome,         Profile    Billing    Logout  
 44 Trials 
29 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pollyea, Daniel Aaron
NCT03573024: Venetoclax and Azacitidine for Non-Elderly Adult Patients with Acute Myeloid Leukemia

Active, not recruiting
2
36
US
Azacitidine, Venetoclax
University of Colorado, Denver, AbbVie
Acute Myeloid Leukemia
06/26
06/27
OV-AML-1231, NCT06384261: A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Recruiting
2
120
Europe, Canada, US
Cusatuzumab, OV-1001, Venetoclax, Azacitidine
OncoVerity, Inc.
Leukemia, Myeloid, Acute
01/27
06/27
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
NCT04914845: KPT-9274 in Patients with Relapsed and Refractory Acute Myeloid Leukemia

Recruiting
1
40
US
KPT-9274
University of Colorado, Denver, Karyopharm Therapeutics Inc
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
02/26
02/27
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
Smith, Andrew
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
NCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Recruiting
3
100
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, placebo
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
11/25
02/32
NCT05976243: A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

Recruiting
3
348
Europe, Canada, Japan, US, RoW
Remibrutinib, Placebo
Novartis Pharmaceuticals
Chronic Inducible Urticaria
03/26
12/28
NCT05513001 / 2022-001034-11: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Active, not recruiting
3
698
Europe, Canada, Japan, US, RoW
LOU064 (blinded), remibrutinib, Placebo, LOU064 (open label)
Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
08/24
02/27
RAPID-I, NCT03684278: Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial

Recruiting
2
290
Europe
Infusion of 5 mg/kg Infliximab, Remicade, Infusion of 10 mg/kg Infliximab, 0.9% Sodium Chloride (Placebo)
University of Liverpool, Bangor University, Liverpool University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom, Merck Sharp & Dohme LLC
Acute Pancreatitis
07/26
03/27
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting
2
154
Europe, Canada, US
Oral EP262, Placebo
Escient Pharmaceuticals, Inc
Chronic Spontaneous Urticaria
06/25
07/25
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Recruiting
N/A
1050
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Amara, Amy
NCT06219629: Parkinson's Disease Progression Study

Recruiting
N/A
70
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
08/25
09/25
Bull, Todd M
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Recruiting
2
20
US
Adempas, Riociguat
University of Colorado, Denver, Bayer
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
12/24
12/24
Cornwell, William K
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Recruiting
2
20
US
Adempas, Riociguat
University of Colorado, Denver, Bayer
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
12/24
12/24
Corr, Bradley R
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
NCT03617679: Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

Active, not recruiting
2
79
US
Rucaparib, Placebo Oral Tablet
University of Colorado, Denver, Clovis Oncology, Inc., National Cancer Institute (NCI)
Metastatic Endometrial Cancer
10/23
12/24
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/24
12/24
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Recruiting
2
53
US
Mirvetuximab Soravtansine, IMGN853, MIRV, Olaparib
University of Colorado, Denver, ImmunoGen, Inc.
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
04/26
12/27
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
Sottile, Peter
NCT03409588: Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty

Recruiting
2
20
US
Adempas, Riociguat
University of Colorado, Denver, Bayer
Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
12/24
12/24
Forsberg, Peter
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
2
18
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
08/24
11/25
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
20-1319.cc, NCT05287568: CC-486 and Venetoclax for Acute Myeloid Leukemia

Recruiting
1
35
US
Venetoclax, ABT-199, Abbvie, CC-486
University of Colorado, Denver, Bristol-Myers Squibb
AML
03/27
03/29
Tytus, Hannah
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Active, not recruiting
1
106
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/26
01/27
Vondran, Kayla
PRISM-MEL-301, NCT06112314: IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma

Recruiting
3
680
Europe, US, RoW
Brenetafusp, IMC-F106C, Nivolumab, OPDIVO, Nivolumab + Relatlimab, OPDUALAG
Immunocore Ltd
Advanced Melanoma
10/27
10/27

Download Options